Clinical Trial Search

Primary: Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs) — 1; 1; 0 Participants

Primary: Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off — 5; 2; 1; 1 Participants

Primary: Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant — 35.9; 41.7; 33.8; 39.6 percentage of participants — p=0.3983

Primary: Plasma Ketone Concentration — 136.97; 177.43; 270.61; 249.3 µmol/L

Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…

Primary: Per-Vessel Sensitivity of CTP in the Detection of Myocardial Perfusion Defects During Pharmacological Stress as Compared to Invasive Angiography. — 79 percentage of…

Primary: Number of Participants Reporting Solicited Injection Site (Tenderness/Pain, Erythema, Swelling) and Systemic Reactions (Fever, Vomiting, Crying Abnormal, Drowsiness…

Primary: Incidence of Adverse Events (AEs) — 1124 Participants

Primary: Change From Baseline in Upper Extremity Muscle Strength — 1; 1 score on a scale — p=0.40

Primary: Change From Baseline in 24-hour Average Hand Pain Intensity, Averaged Over the 7 Days Prior to Week 6 — -1.34; -1.70 Scores on scale — p=0.442

Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters

Primary: Performance of Blood Pressure Referral Threshold — .841 proportion

Primary: Adverse Events — 68; 81 Count of participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW Visit — -0.84; -0.52; 0.43; 0.59 SDS